CEO Roundtable
Increasing Valuation Through Milestone-Driven Development Strategy and Strategic Outsourcing
Wednesday, October 19
9:10 a.m. - 10:10 a.m.
Marina
This roundtable addressed challenges faced by emerging pharma and biotech companies with limited development funds and internal resources. Development strategy must connect product development activities with preclinical and clinical development plans in order to achieve development milestones and build investor confidence for subsequent funding rounds at increased valuation. The panel discussed various issues including what activities and when to internalize versus outsource; regulatory agency interactions; clinical development plans tailored to strategy for out-license, partnering, or registration of the product; what are investors looking for when it comes to value creation and potential upside?
Moderator:
- Jon Court, PhD, Chief Executive Officer, Fulcrum Pharma Developments Ltd
Panelists:
- Chris Ehrlich, Venture Partner, InterWest Partners
- Christopher C. Gallen, MD, PhD, President & CEO, Neuromed Technologies, Inc.
- J. Leighton Read, MD, General Partner, Alloy Ventures, Inc.
- M. Scott Salka, Chief Executive Officer, Ambit, Inc.